NextCure Q3 net loss $6.8M; Avere merger financing grows to $820M, stockholder vote set for Dec 9

NextCure, Inc.

Financing commitments supporting Avere merger rise to ~$820M: prior $320M concurrent private placement plus a new $500M placement; ~$266M satisfied by canceling Avere convertible notes.
Special stockholder meeting set for Dec 9, 2026 (record date Nov 3); S-4 declared effective Nov 6, 2026; combined company expected to trade on Nasdaq as AVRX.
Q3 net loss $6.8M vs $8.6M a year ago; R&D $4.5M (-$1.6M YoY), G&A $4.4M (+$1.6M on $1.8M of merger legal fees), restructuring net gain $2.0M.
Cash and marketable securities $8.7M at Sept 30, 2026, down $33.1M from $41.8M at Dec 31, 2025; $35.2M used in operations, offset by $1.2M ATM proceeds.
Delaware Chancery final order Nov 2, 2026 validated July 2025 reverse split; LNCB74 IND transferred to LigaChem Oct 6; legacy holders to receive CVRs.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.